1-11 of 11
Yin WU
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

Chengcheng Fu, Wenming Chen, Zhen Cai, Lingzhi Yan, Huijuan Wang, Jingjing Shang, Yin Wu, Shuang Yan, Wen Gao, Xiaolan Shi, Xiaoyan Han, Fang Tang, Gaofeng Zheng, Yanling Wen, Xingxing Meng, Wei Zheng, Huamao Wang, Zonghai Li
Journal: Blood
Blood (2023) 142 (Supplement 1): 4845.
https://doi.org/10.1182/blood-2023-184373
Published: 2023
Journal Articles

Mitoxantrone Hydrochloride Liposome, Bortezomib, and Dexamethasone- Based Regimen in Multiple Myeloma Patients with Extramedullary Plasmacytoma: A Pilot Study

Yuan Jian, Nian Liu, Yan-Ru Zhang, Wen Gao, Wen-Ming Chen, Hong-Hu Zhu, Yin Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6650.
https://doi.org/10.1182/blood-2023-188304
Published: 2023
Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimen for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Zhe Zhuang, Ying Tian, Hong Yu, Lei Shi, Wei-wei Tian, Qinhua Liu, Dongmei Zou, Fei Dong, Yanping Ma, Ru Feng, Shuangjiao Liu, Hui Liu, Hongmei Jing, Wanling Sun, Liangming Ma, Li Bao, Rong Fu, Yin Wu, Chen Wenming, Junling Zhuang
Journal: Blood
Blood (2022) 140 (Supplement 1): 12637–12639.
https://doi.org/10.1182/blood-2022-169057
Published: 2022
Journal Articles

Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China

Zhe Zhuang, Lei Shi, Ying Tian, Dongmei Zou, Ru Feng, Fei Dong, Yanping Ma, Hong Yu, Wei-wei Tian, Shuangjiao Liu, Liangming Ma, Rong Fu, Hongmei Jing, Hui Liu, Wanling Sun, Chen Wenming, Yin Wu, Li Bao, Junling Zhuang
Journal: Blood
Blood (2021) 138 (Supplement 1): 4728.
https://doi.org/10.1182/blood-2021-149502
Published: 2021
Journal Articles

Ixazomib Versus Lenalidomide or Ixazomib and Lenalidomide Combination As Maintenance Regimens for Patients with Multiple Myeloma: Interim Analysis of a Multi-Center Prospective Study in China

Zhe Zhuang, Ying Tian, Wei-wei Tian, Hong Yu, Dongmei Zou, Qinhua Liu, Lei Shi, Fei Dong, Yanping Ma, Ru Feng, Shuangjiao Liu, Hui Liu, Hongmei Jing, Li Bao, Wanling Sun, Rong Fu, Liangming Ma, Chen Wenming, Yin Wu, Junling Zhuang
Journal: Blood
Blood (2021) 138 (Supplement 1): 4766.
https://doi.org/10.1182/blood-2021-152542
Published: 2021
Journal Articles

Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Wenming Chen, Chengcheng Fu, Zhen Cai, Zonghai Li, Huijuan Wang, Lingzhi Yan, Yin Wu, Xiaolan Shi, Wen Gao, Shuang Yan, Wei Wang, Xiaoyan Han, Gaofeng Zheng, Yanling Wen, Jun Xiao, Huamao Wang, Xiaole Tang
Journal: Blood
Blood (2021) 138 (Supplement 1): 2821.
https://doi.org/10.1182/blood-2021-150124
Published: 2021
Journal Articles

T(4; 14) Is Not a Poor Prognostic Factor for Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation in New Drug Era

Chuanying Geng, MD, Guangzhong Yang, Wen Gao, MD, Huijuan Wang, Yanchen Li, Yin WU, Huixing Zhou, MD, Zhiyao Zhang, MD, Yuan Jian, Wenming Chen, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30.
https://doi.org/10.1182/blood-2020-140268
Published: 2020
Journal Articles

Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Wenming Chen, MD PhD, Chengcheng Fu, MD PhD, Zhen Cai, MD PhD, Zonghai Li, MD PhD, Huijuan Wang, MD PhD, Lingzhi Yan, MD PhD, Yin Wu, MD PhD, Xiaolan Shi, MD PhD, Wen Gao, MD, Shuang Yan, MD, Wei Wang, MDPhD, Xiaoyan Han, MD PhD, Gaofeng Zheng, MD PhD, Yanling Wen, MD, Jun Xiao, MD, Huamao Wang, PhD, Hong Ma, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–50.
https://doi.org/10.1182/blood-2020-140727
Published: 2020
Journal Articles

Characteristics and Outcome Of Multiple Myeloma (MM) In African Americans (AA) Receiving Novel Agents and Autologous Stem Cell Transplantation (ASCT)

Vishal Bhatnagar, MD, Yin Wu, MD, Olga Goloubeva, Kathleen Ruehle, RN, Todd Milliron, Saul Yanovich, MD, Aaron P. Rapoport, MD, Ashraf Badros, MD
Journal: Blood
Blood (2013) 122 (21): 2951.
https://doi.org/10.1182/blood.V122.21.2951.2951
Published: 2013
Journal Articles

Schedule Dependent Effects of Adoptively Transferred Autologous T Cells After AutoSCT for Myeloma: Accelerated Immune Recovery Is Associated with Improved Event-Free Survival.

Aaron P. Rapoport, MD, Nicole A. Aqui, MD, Edward A. Stadtmauer, MD, Dan T. Vogl, MD, Hong-Bin Fang, PhD, Stephen Janofsky, BS, Jan Storek, MD, PhD, Anne Chew, PhD, Elizabeth Veloso, JD, Gorgun Akpek, MD, MS, Saul Yanovich, MD, Ming T. Tan, PhD, Yin Wu, MD, Alan Cross, MD, Sunita Philip, MPH, Heather Murphy, Rita Bhagat, RN, Yiping Liu, Bruce Levine, PhD, Robert H. Vonderheide, MD, DPhil, Carl H. June, MD
Journal: Blood
Blood (2009) 114 (22): 784.
https://doi.org/10.1182/blood.V114.22.784.784
Published: 2009
Journal Articles

Outcome of African-American (AA) Multiple Myeloma (MM) Patients after Autologous Stem Cell Transplantation (ASCT): A Single-Center Experience.

Yin Wu, MD, Olga Goloubeva, PhD, Kathleen Ruehle, Saul Yanovich, MD, Aaron P. Rapoport, MD, Gorgun Akpek, MD, MS, Ashraf Z. Badros, MD
Journal: Blood
Blood (2008) 112 (11): 3327.
https://doi.org/10.1182/blood.V112.11.3327.3327
Published: 2008